---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331563"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-08-04T11:40:27+00:00"
generated_at: "2026-08-04T11:45:27.919818+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Faeth Therapeutics Q2 2026 net loss $16.0M; cash $186.4M; Phase 2 PIK-201 data expected year-end

## Summary
- Net loss of $16.0M ($2.84 per share) for Q2 2026, compared to $4.9M ($3.91 per share) in Q2 2025.
- Cash, cash equivalents and marketable securities of $186.4M as of June 30, 2026, up from $21.2M at Dec 31, 2025, reflecting $200M PIPE financing.
- Topline results from Phase 2 PIK-201 trial in endometrial cancer on track for year-end 2026.
- First patient dosed in Phase 1b/2 PIK-101 trial in HR+ breast cancer in April 2026.
- Company changed name to Faeth Therapeutics and began trading under ticker FTH on June 16, 2026.

## SEC filing metadata
- accession: 0001193125-26-331563
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-08-04T11:40:27+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/0001193125-26-331563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/d168633d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331563
- JSON: https://secwatch.observer/filing/0001193125-26-331563.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.